Literature DB >> 227957

Antibody-independent neutralization of vesicular stomatitis virus by human complement. II. Formation of VSV-lipoprotein complexes in human serum and complement-dependent viral lysis.

B J Mills, D P Beebe, N R Cooper.   

Abstract

Vesicular stomatitis virus (VSV) is efficiently neutralized by normal, nonimmune human serum without the participation of antibody. Neutralization is complement- (C) dependent and requires the early-acting components of the classical pathway, C1, C4, C2, and C3, but not later-acting C components. In further studies, normal human serum was found to markedly increase the density of a variable but significant proportion of virus-associated RNA and to markedly decrease the density of the remainder of virus-associated RNA. The RNA of increased density was found to be dense ribonucleocapsid cores released from VSV by C-dependent viral lysis mediated through the classical pathway. The released ribonucleocapsid cores found at the bottom of sucrose density gradient after incubation of VSV with human serum were resistant to degradation by proteolytic enzymes. The VSV-derived RNA found floating on the tops of sucrose density gradients performed on serum-treated VSV was infectious virus. The decreased density was due to binding of VSV to human serum lipoproteins (LP), primarily very low density lipoproteins (VLDL). Binding of VLDL to VSV required the presence of the viral envelope and the external glycoprotein, G. Despite the binding of LP to VSV, LP did not neutralize VSV, and LP-depleted sera were fully active in neutralizing VSV. Thus, LP do not represent an accessory factor for the C-dependent neutralization of VSV.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 227957

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Authors:  V Agnello; G Abel; M Elfahal; G B Knight; Q X Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 2.  The complement system: its importance in the host response to viral infection.

Authors:  R L Hirsch
Journal:  Microbiol Rev       Date:  1982-03

3.  Susceptibility of various animals to the vesiculoviruses Isfahan and Chandipura.

Authors:  C R Wilks; J A House
Journal:  J Hyg (Lond)       Date:  1986-10

4.  Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization.

Authors:  John B Johnson; Douglas S Lyles; Martha A Alexander-Miller; Griffith D Parks
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

5.  Complement-Mediated Neutralization of a Potent Neurotropic Human Pathogen, Chandipura Virus, Is Dependent on C1q.

Authors:  Umerali Kunnakkadan; Joydeep Nag; Nisha Asok Kumar; Reshma Koolaparambil Mukesh; Sreenath Muraleedharan Suma; John Bernet Johnson
Journal:  J Virol       Date:  2019-09-12       Impact factor: 5.103

6.  Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus.

Authors:  John B Johnson; Gerald A Capraro; Griffith D Parks
Journal:  Virology       Date:  2008-04-28       Impact factor: 3.616

7.  Susceptibility of various animals to the vesiculovirus Piry.

Authors:  C R Wilks; J A House
Journal:  J Hyg (Lond)       Date:  1984-08

8.  Replication of vesicular stomatitis virus in mouse spleen cells.

Authors:  T T Hecht; W E Paul
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

Review 9.  Neutralizing antiviral antibody responses.

Authors:  R M Zinkernagel; A LaMarre; A Ciurea; L Hunziker; A F Ochsenbein; K D McCoy; T Fehr; M F Bachmann; U Kalinke; H Hengartner
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

10.  A new method for the detection of neutralizing antibodies against mumps virus.

Authors:  Keita Matsubara; Motoko Fujino; Kaoru Takeuchi; Satoshi Iwata; Tetsuo Nakayama
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.